Thrombocytopenia is a primary manifestation of immune thrombocytopenic purpura (ITP) and may occur as a result of hepatitis C, malignancy, and treatment with chemotherapy. There is a need for additional means to treat thrombocytopenia in these settings. Recombinant thrombopoietin-like agents became available after the cloning of thrombopoietin in 1994. In clinical trials, these agents showed some efficacy in chemotherapy-induced thrombocytopenia, but their use was ultimately discontinued due to the development of neutralizing antibodies that cross-reacted with endogenous thrombopoietin and caused thrombocytopenia in healthy blood donors and other recipients. Subsequently, “second-generation” thrombopoietic agents without homology to thrombopoietin were developed. In the past 5 years, these second-generation thrombopoeitic growth factors have undergone substantial clinical development and have demonstrated safety, tolerability and efficacy in subjects with ITP and hepatitis C–related thrombocytopenia. These completed studies, many of which are available only in abstract form, and other ongoing studies suggest that thrombopoietic agents will enhance the hematologist’s ability to manage these and other causes of thrombocytopenia.

Topics:
chemotherapy regimen, purpura, thrombocytopenic, idiopathic, thrombocytopenia, thrombopoietin receptor agonists, hepatitis c, thrombopoietin, thrombocytopenia, chemotherapy induced, romiplostim

Thrombopoietin, the primary circulating hematopoietic growth factor that regulates megakaryocytopoiesis and platelet production, was cloned and characterized in 1994.1,–6 It is the ligand for the thrombopoietin receptor (TPO-R), c-mpl, which is expressed on the surface of megakaryocytes, platelets and primitive stem cells. Based on in vitro and in vivo data, the kinetics of megakaryocyte differentiation and platelet production are such that stimulation of the TPO-R in a normal bone marrow would require 5 to 14 days to manifest itself as an increase in the platelet count, whereas it would require 2 to 3 weeks in an ablated marrow.7 

Identification of human thrombopoietin was followed soon after by the development of recombinant molecules with thrombopoietin-like structure and activity.8,9 Clinical trials with these recombinant products were initiated in patients undergoing chemotherapy and in healthy donors of platelets for transfusion. Further investigation was stopped due to the development of neutralizing antibodies that cross-reacted with endogenous thrombopoietin and caused protracted resistant thrombocytopenia. Thrombocytopenia was most evident in healthy platelet donors who had received 2 or 3 treatments, but was also seen in several patients after chemotherapy for cancer in whom the expected postchemotherapy platelet recovery never occurred.10,11 

The results seen, however, convinced investigators that TPO-R agonists could substantially increase platelet numbers. Therefore, development of less immunogenic peptide and small molecule TPO-R agonists was pursued (Table 1 ). These agents have shown substantial clinical promise in patients with immune thrombocytopenia purpura (ITP) and hepatitis C–related thrombocytopenia.12 –16 Ongoing clinical investigation with these new agents has revealed that they have the potential to be a safe and efficacious means to treat thrombocytopenia in these and other conditions.

In the second half of the 1990s, the use of the now-discontinued recombinant thrombopoietins in the management of thrombocytopenia in patients undergoing both myeloablative and nonmyeloablative chemotherapy was investigated extensively (Table 2 ).

Although clinical development of the early thrombopoietic agents has ceased, no studies using the second-generation TPO-R agonists in CIT have been published. Therefore, the earlier studies will be briefly reviewed here to provide insight into the potential utility of thrombopoietic agents in this setting. In addition, since the earlier agents were removed from clinical trial, overviews of their use were not widely disseminated. Initially, there was much excitement regarding the use of the early recombinant agents as an adjunct to chemotherapy, given the adverse effects of chemotherapy-induced thrombocytopenia (CIT), such as treatment delays, dose reductions, and the side effects of platelet transfusions, most notably alloimmunization.17 It was hoped that these agents would demonstrate similar effects on CIT as granulocyte colony-stimulating factor (G-CSF) had in ameliorating chemotherapy-induced neutropenia.

What if the patient were undergoing nonmyeloablative chemotherapy?

Generally favorable results were observed using recombinant thrombopoietin during nonmyeloablative chemotherapy for solid-tumor malignancies. Thrombopoietic therapy was found to be useful in each of 8 studies listed in the non-myeloablative section of Table 2 .18,–24 In 7 of the 8 studies, an increase in the postchemotherapy platelet nadir and a reduced time to platelet recovery was observed. The requirement for platelet transfusions was reduced in 5 of 7 studies. However, many patients on the placebo arm did not require transfusion, and there was little significant bleeding at the platelet counts in these studies, so the need for exogenously administered thrombopoietin therapy remained unproven. Other clinically relevant endpoints, such as enhanced tumor response to chemotherapy and frequency of dose reductions or delayed initiation of chemotherapy, were generally not extensively studied, although this was specifically examined by Moskowitz et al.60 

What if the patient were undergoing myeloablative chemotherapy?

These studies fall into two clinical settings: induction/consolidation of AML25,–28 and stem cell transplantation.29,–31,62 The 4 studies of recombinant TPO in patients with acute myelogenous leukemia (AML) undergoing induction and/ or consolidation chemotherapy showed no clinical benefit either in terms of ameliorating the platelet nadir or significantly reducing the need for platelet transfusion. One explanation for this difference may be that only very immature megakaryocyte progenitor cells survive the myelotoxic therapy used in leukemia treatment, and these progenitors require weeks to mature. Current studies are exploring administration of these agents prior to chemotherapy, as well as afterwards, in order to circumvent this problem.32 

Three randomized trials of recombinant TPO given for autologous stem cell transplantation showed no overall benefit.31,62,–64 However, the data do support a role for thrombopoietic agents in combination with G-CSF to improve mobilization of hematopoietic progenitor cells to the peripheral blood and thereby enhance yields during peripheral stem cell harvesting.33,34 Clinical consequences of the addition of thrombopoietic agents in this setting remain unknown.

Overall, the studies of thrombopoietic agents in the management of CIT are difficult to interpret due to intertrial variability in study design, study population, dosing strategy and clinical endpoints. The data suggest that thrombopoietic agents in the myeloablative setting may not be very useful; however, use in nonmyeloablative treatment regimens for solid-tumor malignancies shows promise. Given the potential for increasing platelet counts and thereby permitting chemotherapy dose augmentation, this usage of the newer generation of TPO-R agonists is being carefully investigated. The overall efficacy thus far does not appear too different from what one might conclude regarding the use of G-CSF in the chemotherapy-induced neutropenia setting.

Seventeen percent of patients with chronic liver disease from hepatitis C infection have thrombocytopenia,35 and the prevalence of thrombocytopenia correlates with the severity of liver disease.36 Although the thrombocytopenia is generally moderate, it increases the bleeding risk in this coagulopathic population during diagnostic studies (e.g., liver biopsies) and excludes patients from interferon-α (IFN-α)–based antiviral treatment or else requires dose modification. This is of particular concern given that adherence to the therapeutic regimen directly impacts viral containment.37 

The etiology of thrombocytopenia in hepatitis C–related liver disease is multifactorial and includes hypersplenism, antiplatelet antibody-mediated platelet destruction,38,39 and direct cytotoxicity by the virus on megakaryocytes.40 Furthermore, although the thrombocytopenia may not usually be as severe as can be seen in ITP, bleeding occurs more frequently at higher counts, possibly related to comorbid factors such as cryoglobulins, disseminated intravascular coagulation, and impaired production of coagulation factors.41 Patients with more severe disease have decreased TPO production,42,43 and preclinical work showed that a small-molecule thrombopoietin mimetic, NIP-004, prevented IFN-α2b–induced thrombocytopenia in mice.44 Taken together, these findings point to a potential role for TPO-R agonists in the management of patients with hepatitis C–related thrombocytopenia.

A recent randomized, placebo-controlled phase 2 clinical trial examined the efficacy of eltrombopag, an oral non-peptide platelet growth factor, in increasing platelet counts and facilitating the maintenance of antiviral therapy in hepatitis C–infected patients with platelet counts below 70,000/μL.16 Although the results are preliminary, they suggest that thrombopoietic agents may play an important role in the management of this expanding patient population by preventing dose interruptions or reductions as a result of thrombocytopenia. Further clinical investigations with eltrombopag and other TPO-R agonists in this area have been initiated.

Historically, ITP has been classified as an autoimmune disease in which circulating antiplatelet antibodies accelerate peripheral destruction of platelets. Therefore, therapies directed at inhibiting platelet destruction have been the mainstay, including corticosteroids, intravenous immunoglobulin, intravenous anti-D, rituximab, and splenectomy. Recently, evidence has emerged demonstrating that ITP is also a state of platelet underproduction45,–47 in which thrombopoietin generation is not increased in proportion to the severity of thrombocytopenia. Marrow megakaryocytes are thought to be damaged, and their ability to produce platelets in response to thrombopoietin impaired,48 thus dissociating the typically increased number of megakaryocytes in the marrow from an increase in platelet production.

Past attempts to increase platelet production by stimulation of the TPO-R involved a single patient with cyclic autoimmune thrombocytopenia maintained on pegylated megakaryocyte growth and development factor (PEG-MGDF) for 8 years,49 4 patients treated with a single dose of the same agent,50 and work in HIV–related thrombocytopenia. These anecdotes, combined with the aforementioned difficulties in demonstrating unequivocal efficacy of thrombopoietic agents in CIT, were enough to initiate study of ITP with the novel thrombopoietic agents as the primary initial clinical target (Table 1 ). Phase 3 trials have primarily been conducted with two agents, AMG531 and eltrombopag, although trials have also been initiated with AKR501.

AMG531

AMG531 was the first of the second-generation thrombopoeitic agents in clinical trials. It is a recombinant protein composed of a carrier FcR domain and 4 peptide-containing domains that bind the thrombopoietin receptor, thereby stimulating megakaryocytopoiesis. AMG531 is given weekly by subcutaneous injection, and trials have included home injection by patients.

Preclinical studies have shown the ability of AMG531 to increase platelet counts in wild-type mice51 and to reduce the duration and severity of thrombocytopenia in murine models of chemoradiation therapy–induced thrombocytopenia.52 Phase 1 data from healthy human volunteers demonstrated that a single dose of intravenous or subcutaneous AMG531 was safe and tolerable, caused a dose-dependent increase in the platelet count, and did not induce anti-TPO antibodies.53 

Two phase 1/2 multicenter clinical trials of AMG531 in ITP have been published.12,13 Treated patients had chronic, relatively severe ITP and were typically the investigators’ most difficult-to-treat patients, who could not otherwise be easily managed. Platelet counts at entry were required to be less than 30,000/μL unless the patient was on a stable dose of steroids. A response was defined as achieving a platelet count of 50,000/μL and doubling of the initial count. Both studies showed that weekly subcutaneous injections of at least 1 μg/kg were efficacious, with the median time to a platelet increase ranging from 5 to 10 days. At the highest dose, one recipient who had undergone splenectomy and had had ITP for more than 10 years had a platelet count higher than 106/μL.12 Weekly dosing increased the response rate but also revealed fluctuating platelet counts on stable dosing in certain patients. No consistent effects on red blood cell or white blood cell counts were seen. These studies included primarily, but not solely, patients who had failed to respond to splenectomy. In both studies, AMG531 was well tolerated, with the most frequently reported adverse effect being self-limited headache that did not require drug discontinuation. Importantly, no anti-TPO or anti-AMG531 antibodies were detected.

A long-term, ongoing extension study has been reported in abstract form. It suggests that AMG531 will safely support an adequate platelet count (50–200,000/μL) in most patients, in some for more than 2 years, with weekly injections of doses up to 10 μg/kg/dose.54 However, at least 2 patients on this long-term study developed reversible marrow reticulin fibrosis, raising questions regarding the frequency of this complication with long-term use. In pre-clinical and clinical studies using PEG-MGDF, an increase in bone marrow reticulin, which was reversible on discontinuation of the drug, has also been reported.55 –57 This is presumably a result of enhanced megakaryocyte secretion of growth factors inducing fibrosis, such as transforming growth factor-beta. The significance of this reversible, treatment-induced effect in the setting of ITP is unknown. Collectively, these clinical studies of AMG531 suggest that it appears to be a safe, therapeutic alternative to conventional immunomodulatory agents in most patients with ITP.

Recently completed AMG531 studies

Two multicenter, placebo-controlled, randomized studies enrolling 62 and 63 patients, respectively, investigated the efficacy of weekly dosing of AMG531 in adults with chronic ITP for a 6-month period. One study enrolled only patients who had undergone splenectomy, while the other enrolled only patients who had not had a splenectomy. The final results are not yet available, but the preliminary data appear promising.

Eltrombopag

Eltrombopag is an orally active, small-molecule TPO-R agonist. It is taken daily and requires an empty stomach for 2 hours both before and after ingestion. Initial studies showed that daily doses of 30 mg, 50 mg, and 75 mg were active in increasing the platelet count in healthy volunteers.58 Platelet increases have been seen in responders at 1 week when the first on-treatment count has been obtained; earlier counts in patients with ITP have not been tested. The efficacy, safety, and tolerability of this agent were tested in a randomized controlled trial including the same 3 doses of eltrombopag compared with placebo in 117 adults with chronic ITP.14 The 117 patients enrolled worldwide in this study had chronic ITP with had platelet counts 30,000/μL or less, and had failed at least one previous course of therapy for ITP. In addition, almost 50% had undergone splenectomy. A response was defined as a platelet count of 50,000/μL or more after 6 weeks of therapy. At this time, the preliminary results are promising but are available only in abstract form.

A second large randomized, placebo-controlled trial of eltrombopag has been completed that is similar in entry criteria and study endpoints to that of the first study.15 Preliminary analysis suggests that it confirms the results of the first study, i.e., there is efficacy of 50 mg daily compared with placebo over 6 weeks of use in patients with chronic ITP. In addition, bleeding signs and symptoms were reduced compared with responders, and no important toxicity was observed.

Ongoing and future eltrombopag studies

Eltrombopag is being evaluated in several other ongoing studies: a randomized trial in which eltrombopag is being compared to placebo for 6 months; a long-term extension study in which patients who have completed previous trials are eligible to continue long-term use of the agent; and a study in which 6-week courses of study drug separated by 4-week washout periods allows comparison of the efficacy of the agent to itself with repeated use.

AKR-501

Results of a trial of another active oral thrombopoietic agent, AKR-501, showed that even single doses substantially raised the platelet count in healthy volunteers.59 The drug was well tolerated, and studies in ITP are ongoing.

SB-559448

SB-559448 is an oral, nonpeptide, small-molecule TPO-R agonist. It has been investigated in healthy volunteers in a phase 1, single-blind, randomized fashion to cause a dose-dependent increase in platelet count with demonstrated safety.60 Studies in ITP are planned.

Other agents with in vitro activity have also been developed by several companies. Which ones get developed and which, if any, will have specific clinical advantages is unknown at this time.

There are several considerations involving the use of thrombopopietic agents in ITP and in other disease states. First, AMG531 is the only agent under investigation that has thus far been reported with long-term use. Therefore, whether the finding in a small number of treated patients of reticulin fibrosis is specific to this agent or would be observed with all thrombopoietic growth factors remains to be clarified. In this regard, AMG531 competes with TPO for the TPO-R and signals, as does TPO itself, via the JAK-STAT, P38 MAPK, and AKT pathways. The oral, small-molecule, thrombopoietic agents (eltrombopag and AKR501) do not compete with TPO for the TPO-R, and eltrombopag appears to signal via the JAK-STAT and P38 MAPK but not the AKT pathway. These differences suggest that the effects of these two compounds may not be identical, for better or worse, to those of TPO itself and AMG531. Second, the kinetics of platelet increase in responders appear to differ from those of IVIG or IV anti-D. A single dose of 1 g/kg of IVIG or 75 μg/kg IV anti-D might increase the platelet count overnight, with a peak effect seen at 4 to 6 days, but with a return to baseline by 2 to 3 weeks. In contrast, the platelet increase with a single dose of a thrombopoietic agent (or with daily doses beginning on day 1) would demonstrate the first clear platelet response by days 5 to 7, peak between then and day 14, and return to baseline at day 21. Finally, a major concern with these agents is that they will not only dramatically increase the platelet counts but also induce platelet activation, either because the newly produced platelets may be large and more functional or because of direct stimulation of the platelet via the TPO-R. Thus far, there has been no clinical evidence of increased thrombosis in treated patients, but further studies including analyses of platelet function in patients with ITP are required.

The newly developed thrombopoietic agents appear to dramatically increase the platelet count in most patients with ITP and with hepatitis C–induced thrombocytopenia. These platelet increases can be sustained by repeated (daily or weekly) drug administration, with dose adjustment depending upon the platelet count. Beneficial effects of these newer agents in CIT have yet to be demonstrated. It is anticipated that these agents will be clinically effective in patients who are not receiving myeloablative chemotherapy, but whether this will translate into a survival advantage or allow avoidance of platelet transfusions is uncertain and will require study. Safety and tolerability have thus far been demonstrated for the two most widely used agents, AMG531 and eltrombopag. Issues of concern include (1) whether thrombosis will be seen in responders in clinical practice, and (2) whether there will be a significant incidence of reticulin fibrosis with prolonged usage, whether this will be an effect seen with all thrombopoeitic agents, and whether it will be reversible in all cases. Regarding hypercoagulability, preliminary studies suggest that AMG531 and eltrombopag do not lead to a high incidence of clinical thrombotic events, but more experience is needed. Additional settings in which TPO-R agonists may be of use in the future include myelodysplastic syndromes, inherited thrombocytopenias, neonatal thrombocytopenia, and for enhancing the yield of platelets from healthy donors, if historic safety concerns are alleviated.61 

The bottom line for the thrombopoietic agents, based on the clinical trials reported thus far, is that they appear to be safe, tolerable, and very effective. In the future, if further trials confirm the ones performed thus far, these agents may become widely used and have a major impact on the clinical care of patients with ITP, hepatitis C, and other thrombocytopenias.

Table 1.

Published studies of the second-generation thrombopoietic agents.

Agent, structure; route and frequency of administrationRef.TrialNo. of patientsBaseline platelet countsDoseTreatment periodTime to responsePlatelet responseToxicityThrombotic events?
Abbreviations: HEP C-ITP, hepatitis C virus–associated thrombocytopenia 
AMG531 Recombinant TPO-R protein with carrier Fc domain; Once weekly subcutaneous injection 53  Phase 1 48 healthy controls NA 0.3 to 10 mg/kg IV or 0.1 to 2.0 mg/kg SC or placebo Single dose Peak response 12–16 d NA Well tolerated, no serious adverse events. Most common toxicity mild headache or sore throat. No 
 12  Phase 1 24 Median platelet count 11 x 109/mL All had platelets <30 x 109/L Cohorts ranging from 0.2 to 10 mg/kg/wk 6 wks Median time to targeted response 5–10 d Platelet count of > 50 x 109/L achieved in 7/12 patients at doses >3 mg Well tolerated, most frequent adverse effect was self-limiting mild headache. 4 had worsening of thrombocytopenia after treatment. No 
 12  Phase 2 21 Median platelet count 16 x 109/mL All had platelets <30 x 109/L Randomly assigned to 1, 2 or 6 μg/kg/wk 6 wks Median time to response 5–10 d 10/16 achieved target platelet count (50–450 x 109/L) with 1 or 3 mg/kg/wk  No 
 13  Phase 1–2 16 Median platelet count 14.5; all had platelets <30 x 109/L Cohorts ranging from 30 to 500 mg/wk 3 wks Median of 10 d (range 5–13 d) Platelet counts in 12/15 patients increased to > 20 and in 8/15 to > 100 x 109/L Generally well tolerated, most common effect mild-mod headache. 1 patient had worsening of thrombocytopenia after treatment and 1 had transient increase in serum lactate dehydrogenase No 
 54  Phase 3 104 enrolled; study ongoing — — up to 96 wks — Mean platelet count 100 wk 1–24 x 109/L and 131 x 109/L wk 25–48; 6/12 pt able to discontinue concurrent steroids Headache most common adverse event. 4 pts had serious treatment- related adverse events, 3 of whom were withdrawn. Transverse sinus thrombosis in 1 pt 
Eltrombopag Small-molecule, nonpeptide TPO-R agonist; Once daily, oral capsule (on empty stomach) 58  Phase 1 73 healthy male controls NA Cohorts of 5–75 mg/d with placebo 10 d Consistent increase started after 8 days of daily dosing; 16 days to peak increase NA No treatment-related adverse events reported. No; no effect of treatment on platelet aggregation and activation 
 14  Phase 2 117 Platelets ≤30 x 109/L Randomly assigned to placebo, 30 mg, 50 mg or 75 mg 6 wks Preliminary results encouraging, no major toxicity — — No 
 16  Phase 2 74 HEP C-ITP Platelets 20–70 x 109/L Randomly assigned to placebo, 30 mg, 50 mg or 75 mg 4 wks Preliminary results encouraging, no major toxicity — — No 
AKR-501 Small-molecule TPO-R agonist; Oral, once daily 59  Phase 1 63 healthy volunteers NA Cohorts of 3–100 mg or placebo 14 d Dose-dependent increases seen NA No serious drug-related adverse experiences reported at any dose. No 
Agent, structure; route and frequency of administrationRef.TrialNo. of patientsBaseline platelet countsDoseTreatment periodTime to responsePlatelet responseToxicityThrombotic events?
Abbreviations: HEP C-ITP, hepatitis C virus–associated thrombocytopenia 
AMG531 Recombinant TPO-R protein with carrier Fc domain; Once weekly subcutaneous injection 53  Phase 1 48 healthy controls NA 0.3 to 10 mg/kg IV or 0.1 to 2.0 mg/kg SC or placebo Single dose Peak response 12–16 d NA Well tolerated, no serious adverse events. Most common toxicity mild headache or sore throat. No 
 12  Phase 1 24 Median platelet count 11 x 109/mL All had platelets <30 x 109/L Cohorts ranging from 0.2 to 10 mg/kg/wk 6 wks Median time to targeted response 5–10 d Platelet count of > 50 x 109/L achieved in 7/12 patients at doses >3 mg Well tolerated, most frequent adverse effect was self-limiting mild headache. 4 had worsening of thrombocytopenia after treatment. No 
 12  Phase 2 21 Median platelet count 16 x 109/mL All had platelets <30 x 109/L Randomly assigned to 1, 2 or 6 μg/kg/wk 6 wks Median time to response 5–10 d 10/16 achieved target platelet count (50–450 x 109/L) with 1 or 3 mg/kg/wk  No 
 13  Phase 1–2 16 Median platelet count 14.5; all had platelets <30 x 109/L Cohorts ranging from 30 to 500 mg/wk 3 wks Median of 10 d (range 5–13 d) Platelet counts in 12/15 patients increased to > 20 and in 8/15 to > 100 x 109/L Generally well tolerated, most common effect mild-mod headache. 1 patient had worsening of thrombocytopenia after treatment and 1 had transient increase in serum lactate dehydrogenase No 
 54  Phase 3 104 enrolled; study ongoing — — up to 96 wks — Mean platelet count 100 wk 1–24 x 109/L and 131 x 109/L wk 25–48; 6/12 pt able to discontinue concurrent steroids Headache most common adverse event. 4 pts had serious treatment- related adverse events, 3 of whom were withdrawn. Transverse sinus thrombosis in 1 pt 
Eltrombopag Small-molecule, nonpeptide TPO-R agonist; Once daily, oral capsule (on empty stomach) 58  Phase 1 73 healthy male controls NA Cohorts of 5–75 mg/d with placebo 10 d Consistent increase started after 8 days of daily dosing; 16 days to peak increase NA No treatment-related adverse events reported. No; no effect of treatment on platelet aggregation and activation 
 14  Phase 2 117 Platelets ≤30 x 109/L Randomly assigned to placebo, 30 mg, 50 mg or 75 mg 6 wks Preliminary results encouraging, no major toxicity — — No 
 16  Phase 2 74 HEP C-ITP Platelets 20–70 x 109/L Randomly assigned to placebo, 30 mg, 50 mg or 75 mg 4 wks Preliminary results encouraging, no major toxicity — — No 
AKR-501 Small-molecule TPO-R agonist; Oral, once daily 59  Phase 1 63 healthy volunteers NA Cohorts of 3–100 mg or placebo 14 d Dose-dependent increases seen NA No serious drug-related adverse experiences reported at any dose. No 
View Large
Table 2.

Trials involving exogenous TPO administration in chemotherapy-induced thrombocytopenia.

TrialForm of exogenous thrombopoietinNo. pts.Clinical settingWas administration of exogenous TPO deemed useful overall?Were platelet transfusions avoided?Were platelet nadirs less low?Were delays in chemotherapy administration or reduction in dose avoided?
*Phase 1/2 study. 
†Phase 3 study. 
Abbreviations: PEG-rHuMGDF, pegylated recombinant human megakaryocyte growth and development factor; rhTPO, recombinant human thrombopoietin; AML, acute myeloid leukemia; ICE, ifosphomide, carboplatin, etoposide; ASCT, autologous stem cell transplantation; NR, not reported 
Studies in nonmyeloablative chemotherapy regimens for solid tumors 
    Basser et al18  PEG-rHuMGDF 41 Advanced cancer Yes NR No No 
    Fanucci et al19  PEG-rHuMGDF 53 Lung cancer Yes NR Yes NR 
    Crawford et al20  PEG-rHuMGDF 40 Lung cancer Yes Yes Yes NR 
    Basser et al21  PEG-rHuMGDF 68 Advanced cancer Yes No Yes NR 
    Vadhan-Raj et al22  rhTPO 29 Gynecological tumors Yes Yes Yes Yes 
    Vadhan-Raj et al32  rhTPO 66 Sarcoma Yes Yes Yes NR 
    Angiolillo et al24  rhTPO 12 Pediatric solid tumor Yes Yes Yes NR 
    Moskowitz et al62  PEG-rHuMGDF 41 Relapsed and refractory aggressive non-Hodgkin lymphoma receiving ICE prior to ASCT Yes Yes Yes Yes 
Studies in chemotherapy regimens for leukemia 
    Cripe et al25  rhTPO 28 AML induction No NR NR NR 
    Archimbaud et al26  PEG-rHuMGDF 108 AML induction, consolidation No No No NR 
    Schiffer et al28  PEG-rHuMGDF 57 AML induction, consolidation No No No NR 
    Geissler et al27  PEG-rHuMGDF 88 AML consolidation No No No NR 
Studies in ablative chemotherapy prior to hematopoietic stem cell transplantation (HSCT) 
    Nash et al63  rhTPO 38 Patients with delayed platelet recovery after HSCT Kinetics of platelet recovery not dose related and therefore efficacy inconclusive. NR NR NR 
    Wolff et al64  rhTPO 33 after HSCT Kinetics of platelet recovery not dose related and therefore efficacy inconclusive. NR NR NR 
    Schuster et al31  PEG-rHuMGDF 75*/64† Autologous HSCT in patients with breast cancer Inconclusive Yes in phase 1/2 No in phase 3 NR NR 
TrialForm of exogenous thrombopoietinNo. pts.Clinical settingWas administration of exogenous TPO deemed useful overall?Were platelet transfusions avoided?Were platelet nadirs less low?Were delays in chemotherapy administration or reduction in dose avoided?
*Phase 1/2 study. 
†Phase 3 study. 
Abbreviations: PEG-rHuMGDF, pegylated recombinant human megakaryocyte growth and development factor; rhTPO, recombinant human thrombopoietin; AML, acute myeloid leukemia; ICE, ifosphomide, carboplatin, etoposide; ASCT, autologous stem cell transplantation; NR, not reported 
Studies in nonmyeloablative chemotherapy regimens for solid tumors 
    Basser et al18  PEG-rHuMGDF 41 Advanced cancer Yes NR No No 
    Fanucci et al19  PEG-rHuMGDF 53 Lung cancer Yes NR Yes NR 
    Crawford et al20  PEG-rHuMGDF 40 Lung cancer Yes Yes Yes NR 
    Basser et al21  PEG-rHuMGDF 68 Advanced cancer Yes No Yes NR 
    Vadhan-Raj et al22  rhTPO 29 Gynecological tumors Yes Yes Yes Yes 
    Vadhan-Raj et al32  rhTPO 66 Sarcoma Yes Yes Yes NR 
    Angiolillo et al24  rhTPO 12 Pediatric solid tumor Yes Yes Yes NR 
    Moskowitz et al62  PEG-rHuMGDF 41 Relapsed and refractory aggressive non-Hodgkin lymphoma receiving ICE prior to ASCT Yes Yes Yes Yes 
Studies in chemotherapy regimens for leukemia 
    Cripe et al25  rhTPO 28 AML induction No NR NR NR 
    Archimbaud et al26  PEG-rHuMGDF 108 AML induction, consolidation No No No NR 
    Schiffer et al28  PEG-rHuMGDF 57 AML induction, consolidation No No No NR 
    Geissler et al27  PEG-rHuMGDF 88 AML consolidation No No No NR 
Studies in ablative chemotherapy prior to hematopoietic stem cell transplantation (HSCT) 
    Nash et al63  rhTPO 38 Patients with delayed platelet recovery after HSCT Kinetics of platelet recovery not dose related and therefore efficacy inconclusive. NR NR NR 
    Wolff et al64  rhTPO 33 after HSCT Kinetics of platelet recovery not dose related and therefore efficacy inconclusive. NR NR NR 
    Schuster et al31  PEG-rHuMGDF 75*/64† Autologous HSCT in patients with breast cancer Inconclusive Yes in phase 1/2 No in phase 3 NR NR 
View Large
1
de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand.
Nature
.
1994
;
369
:
533
–538.
2
Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo.
Nature
.
1994
;
369
:
565
–568.
3
Wendling F, Maraskovsky E, Debili N, et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis.
Nature
.
1994
;
369
:
571
–574.
4
Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl.
Cell
.
1994
;
77
:
1117
–1124.
5
Sohma Y, Akahori H, Seki N, et al. Molecular cloning and chromosomal localization of the human thrombopoietin gene.
FEBS Lett
.
1994
;
353
:
57
–61.
6
Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production.
Proc Natl Acad Sci U S A
.
1994
;
91
:
11104
–11108.
7
Kaushansky K. Thrombopoietin.
N Engl J Med
.
1998
;
339
:
746
–754.
8
Ulich TR, del Castillo J, Yin S, et al. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice.
Blood
.
1995
;
86
:
971
–976
9
Neelis KJ, Hartong SC, Egeland T, Thomas GR, Eaton DL, Wagemaker G. The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/ macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys.
Blood
.
1997
;
90
:
2565
–2573.
10
Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin.
Blood
.
2001
;
98
:
3241
–3248.
11
Basser RL, O’Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor.
Blood
.
2002
;
99
:
2599
–2602.
12
Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.
N Engl J Med
.
2006
;
355
:
1672
–1681. Erratum in: N Engl J Med. 2006;355:2054.
13
Newland A, Caulier MT, Kappers-Klunne M, et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura.
Br J Haematol
.
2006
;
135
:
547
–53.
14
Bussel JB, Cheng G, Saleh M, et al. Analysis of bleeding in patients with Immune Thrombocytopenic Purpura (ITP): a randomized, double-blind, placebo-controlled trial of Eltrombopag, an oral platelet growth factor [abstract].
Blood
.
2006
;
108
:
475a
.
15
Bussel JB, Shamsi TS, Cheng G, et al. Eltrombopag, an oral, non-peptide platelet growth factor, increases platelet counts and decreases bleeding in patients with idiopathic thrombocytopenic purpura in a Phase III study [abstract]. 2007 XXIst Congress of the International Society on Thrombosis and Haemostasis meeting abstracts. Abstract no. O-S-019.
16
McHutchison JG, Afdhal NH; Dusheiko G, et al. Eltrombopag, an oral platelet growth factor, facilitates initiation of interferon therapy in subjects with HCV associated thrombocytopenia [abstract]. 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD),
2006
.
17
Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group.
N Engl J Med
.
1997
;
337
:
1861
–1869.
18
Basser RL, Rasko JEJ, Clarke K, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
Blood
.
1997
;
89
:
3118
–3128.
19
Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.
N Engl J Med
.
1997
;
336
:
404
–409.
20
Crawford J, Glaspy J, Belani C, et al. A randomized, placebo-controlled, blinded, dose scheduling trial of pegylated recombinant human megakaryocyte growth and development factor in non small cell lung cancer patients treated with paclitaxel and carboplatin during multiple cycles of chemotherapy.
Proc ASCO
.
1998
; Abstract no.
285
21
Basser RL, Underhill C, Davis I, et al. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer.
J Clin Oncol
.
2000
;
18
:
2852
–2861.
22
Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.
Ann Intern Med
.
2000
;
132
:
364
–368.
23
Vadhan-Raj S, Kavanagh JJ, Freedman RS, et al. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
Lancet
.
2002
;
359
:
2145
–2152.
24
Angiolillo AL, Davenport V, Bonilla MA, et al. A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children’s Oncology Group experience.
Clin Cancer Res
.
2005
;
11
:
2644
–2650.
25
Cripe L, Neuberg D, Tallman M, et al. A pilot study of recombinant human thrombopoietin and GM-CSF following induction therapy in patients older than 55 years with acute myelogenous leukemia [abstract].
Blood
.
2000
;
96
:
616a
.
26
Archimbaud E, Ottmann OG, Liu Yin JA, et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia.
Blood
.
1999
;
94
:
3694
–3701.
27
Geissler K, Yin JA, Ganser A, et al. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia—a randomized, placebo-controlled, double-blind safety and efficacy study.
Ann Hematol
.
2003
;
82
:
677
–683.
28
Schiffer CA, Miller K, Larson RA, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia.
Blood
.
2000
;
95
:
2530
–2535.
29
Bolwell B, Vredenburgh J, Overmoyer B, et al. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation.
Bone Marrow Tranplantation
.
2000
;
26
:
141
–145.
30
Fields KK, Crump M, Bence-Bruckler I, et al. Use of PEG-rHuMGDF in platelet engraftment after autologous stem cell transplantation.
Bone Marrow Transplantation
.
2000
;
26
:
1083
–1088.
31
Schuster MW, Beveridge R, Frei-Lahr D, et al. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
Exp Hematol
.
2002
;
30
:
1044
–1050.
32
Vadhan-Raj S, Patel S, Bueso-Ramos C, et al. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thromobocytopenia.
J Clin Oncol
.
2003
;
21
:
3158
–3167.
33
Somlo G, Sniecinski I, ter Veer A, et al. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.
Blood
.
1999
;
93
:
2798
–2806.
34
Ippoliti C, Benyunes M, Miller LL, et al. Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization.
Biol Blood Marrow Transplant
.
2002
;
8
:
550
–556.
35
Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d’Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l’Hepatite C.
Medicine (Baltimore)
.
2000
;
79
:
47
–56.
36
Wang CS, Yao WJ, Wang ST, Chang TT, Chou P. Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: implications from a survey of a community with hyperendemic HCV infection.
Clin Infect Dis
.
2004
;
39
:
790
–796.
37
McHutchison JG, Manns M, Patel K, et al; International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.
Gastroenterology
.
2002
;
123
:
1061
–1069.
38
Hernández F, Blanquer A, Linares M, López A, Tarín F, Cerveró A. Autoimmune thrombocytopenia associated with hepatitis C virus infection.
Acta Haematol
.
1998
;
99
:
217
.
39
Iga D, Tomimatsu M, Endo H, Ohkawa S, Yamada O. Improvement of thrombocytopenia with disappearance of HCV RNA in patients treated by interferon-alpha therapy: possible etiology of HCV-associated immune thrombocytopenia.
Eur J Haematol
.
2005
;
75
:
417
–423.
40
Garcia-Suarez J, Burgaleta C, Hernanz N, Albarran F, Tobaruela P, Alvarez-Mon M. HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant alpha2b-interferon therapy.
Br J Haematol
.
2000
;
110
:
98
–103.
41
Rajan SK, Espina BM, Liebman HA. Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura.
Br J Haematol
.
2005
;
129
:
818
–824.
42
Giannini E, Borro P, Botta F, et al. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis.
J Hepatol
.
2002
;
37
:
572
–577.
43
Giannini E, Botta F, Borro P, et al. Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection.
Am J Gastroenterol
.
2003
;
98
:
2516
–2520.
44
Nakamura T, Miyakawa Y, Miyamura A, et al. A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis.
Blood
.
2006
;
107
:
4300
–4307.
45
McMillan R, Nugent D. The effect of antiplatelet autoantibodies on megakaryocytopoiesis [review].
Int J Hematol
.
2005
;
81
:
94
–99.
46
Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance.
J Clin Invest
.
1987
;
80
:
33
–40.
47
Gernsheimer T, Stratton J, Ballem PJ, Slichter SJ. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura.
N Engl J Med
,
1989
;
321
:
760
–761.
48
Houwerzijl EJ, Blom NR, van der Want JJ, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura.
Blood
.
2004
;
103
:
500
–506.
49
Rice L, Nichol JL, McMillan R, Roskos LK, Bacile M. Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy.
Am J Hematol
.
2001
;
68
:
210
–214.
50
Nomura S, Dan K, Hotta T, Fujimura K, Ikeda Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura.
Blood
.
2002
;
100
:
728
–730.
51
Broudy VC, Lin HL. AMG 531 stimulates megakaryopoiesis in vitro by binding to Mpl.
Cytokine
.
2004
;
25
:
52
–60.
52
Hartley C, McElroy T, Molineux G, et al. The novel thrombopoietic agent AMG 531 is effective in pre-clinical models of chemo/radiotherapy induced thrombocytopenia.
Proc Am Assn Cancer Res
.
2005
;
46
:
1233
.
53
Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand.
Clin Pharmacol Ther
.
2004
;
76
:
628
–638.
54
Kuter D, Bussel JB, George J, et al. Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 48-week update [abstract].
Blood
.
2006
;
108
:
476a
.
55
Ulich TR, del Castillo J, Senaldi G, et al. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice.
Blood
.
1996
;
87
:
5006
–5015.
56
Yanagida M, Ide Y, Imai A, et al. The role of transforming growth factor-β in PEG-rHuMGDF-induced reversible myelofibrosis in rats.
Br J Haematol
.
1997
;
99
:
739
–745.
57
Douglas VK, Tallman MS, Cripe LD, Peterson LC. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders.
Am J Clin Pathol
.
2002
;
117
:
844
–850.
58
Jenkins JM, Williams D, Deng Y, et al. Phase I clinical study of eltrombopag, an oral, non-peptide thrombopoietin receptor agonist.
Blood
.
2007
;
109
:
4739
–4741.
59
Desjardins RE, Tempel DL, Lucek R, Kuter DJ. Single and multiple oral doses of AKR-501 (YM477) increase the platelet count in healthy volunteers [abstract].
Blood
.
2006
;
108
:
477a
.
60
Su S-F, Peng B, Williams D, et al. A phase I study to investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of an oral platelet growth factor (SB-559448) in healthy subjects [abstract].
Blood
.
2006
;
108
:
1072a
.
61
Goodnough LT, Kuter DJ, McCullough J, et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin.
Blood
.
2001
;
98
:
1346
–1351.
62
Moskowitz C, Hamlin P, Gabrilove J, et al. Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma.
Ann Oncol
.
2007
; prepublished Sept 14.
63
Nash RA, Kurzrock R, DiPersio J, et al. A phase 1 trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplant.
Biol Blood Marrow Transplant
.
2000
;
6
:
25
–34.
64
Wolff SN, Herzig R, Lynch J, et al. Recombinant humna throbmopoietin (rhTPO) after autologous bone marrow transplantation: a phase 2 pharmacokinetic and pharmakodynamic study.
Bone Marrow Transplant
.
2001
;
26
:
261
–268.

Author notes

1

University of Connecticut Health Center, Farmington, Connecticut

2

Weill Medical College of Cornell University; New York Presbyterian Hospital, New York, New York

2007